论文部分内容阅读
目的:探讨转移性肝癌行介入治疗的临床疗效及影响预后因素。方法:收集我院行介入治疗的72例转移性肝癌患者,其中原发癌灶行手术切除者34例,未手术切除原发灶者38例;通过DSA造影证实72例患者中,病灶为乏血供患者30例,富血供患者27例,中等血供15例,对于肿瘤病灶为富血供、中等血供患者进行肝动脉化疗栓塞(TACE);乏血供病灶行肝动脉灌注化疗。结果:原发癌灶手术切除组半年生存率(76.5%),较未手术切除者(36.8%)具有明显性差异(P<0.05)。肝动脉化疗栓塞治疗组患者半年生存率(78.9%),较肝动脉化疗药物灌注治疗组患者(29.4%)具有高度显著性差异(P<0.01)。结论:转移性肝癌患者,如果患者情况良好,应尽可能切除原发癌灶,并辅以化疗,局部治疗等综合治疗。转移性肝癌根据其血供不同选择相应的介入治疗方式,可取得较好的临床效果。
Objective: To investigate the clinical efficacy and prognostic factors of interventional treatment of metastatic liver cancer. Methods: Totally 72 patients with metastatic liver cancer underwent interventional therapy in our hospital. Among them, 34 patients underwent primary resection and 38 patients did not undergo surgical resection. Among 72 patients confirmed by DSA angiography, the lesions were scarce Thirty cases of blood supply, 27 cases of rich blood supply for patients, 15 cases of moderate blood supply, for the tumor lesions for blood supply, moderate blood for patients with transcatheter arterial chemoembolization (TACE); lack of blood supply to the lesion hepatic artery infusion chemotherapy. Results: The half-year survival rate of primary resection group (76.5%) was significantly lower than that of non-surgical resection group (36.8%) (P <0.05). The half-year survival rate (78.9%) in patients receiving hepatic arterial chemoembolization was significantly higher than that in patients receiving hepatic arterial infusion chemotherapy (29.4%) (P <0.01). Conclusion: Patients with metastatic liver cancer, if the patient is in good condition, should resection of primary foci as much as possible, supplemented by chemotherapy, local treatment and other comprehensive treatment. Metastatic liver cancer according to their blood supply corresponding to the appropriate interventional treatment can achieve better clinical results.